Australia’s TGA approves remdesivir while Gilead reports reduced mortality risk
The Therapeutic Goods Administration (TGA) of Australia has awarded provisional approval for the use of Gilead Sciences’ remdesivir (Veklury) to
Author: Tamas Sohajda
Cyclolab R&D Director
Gilead prices remdesivir at 390$/vial for governments
Daniel O’Day, Chairman & CEO, Gilead Sciences posted an open letter yesterday, to share pricing indications for Gilead anti-COVID19 treatment,
Cyclo Therapeutics Reports on Eighteen Month Expanded Access Program in Single Alzheimer’s Patient
Cyclo Therapeutics, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C
Gilead to Initiate Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years
Set-up of an upcoming clinicl trial has been posted with the primary objectives of this study are to evaluate the
A new country to approve remdesivir for COVID-19 treatment: Israel
Israel approved on Tuesday the use of Gilead Sciences Inc’s antiviral drug remdesivir for the treatment of patients with COVID-19
Underdog Pharmaceuticals Announces MD.USE Partnership and Technology Acquisition
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed
Eva Pharma, DRL, Biocon and Zydus Cadila added to Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
Conditional approval of Veklury® (SBECD-enabled remdesivir) for COVID-19 infection in Singapore
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts informed healthcare professionals on
Takeda Announces Data from the Phase 2 Trial of SBECD-enabled Pevonedistat Plus Azacitidine
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Ligand CEO Issues Letter to Captisol Customers
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The